Humira sales approach $20 billion
Add Axios as your preferred source to
see more of our stories on Google.
Global sales of Humira, the blockbuster drug that treats autoimmune diseases like arthritis and psoriasis, hit $19.9 billion in 2018, an 8.2% increase from 2017, AbbVie reported Friday. AbbVie has collected more than $115 billion in global Humira sales since 2010, 58% of which has come from the U.S.
The bottom line: AbbVie has made and will continue to make a lot of money from Humira. But cheaper copycat versions in Europe are expected to erode sales by $2 billion this year, which sent AbbVie's stock reeling.
By the numbers: A 2-pen box of Humira in the U.S. now retails for almost $5,200, following AbbVie's 6.2% price increase on the medicine. Rebates for Humira average around 40%, so that means U.S. patients who are on typical doses are paying more than $40,000 per year for Humira — the approximate cost of a Ford F-150 pickup truck and a little less than a Tesla Model 3.
